AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
Professor C.H.J. van Eijck, MD, PhD Professor C.H.J. van Eijck, MD, PhD Ampligen® (rintatolimod) has…
Indonesia’s KAI Launches Farmer-Trader Train, Expands Facial Recognition Tech Ahead of 2025/2026 Holiday Travel Surge
TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations
Criminal IP Reveals Global React2Shell RCE Exposure Across React Server Components
Dental Digital Launches Marketing Services for Dental Practices